
Sanofi SA (NASDAQ:SNY) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101), for alpha-1 antitrypsin deficiency (AATD) emphysema.
AATD causes emphysema when the body doesn’t produce enough of the protective alpha-1 antitrypsin (AAT) protein, leading to a breakdown of the lung’s air sacs (alveoli).